Central Bank & Trust Co. Has $1.09 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

by · The Cerbat Gem

Central Bank & Trust Co. cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 3.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 2,068 shares of the biopharmaceutical company’s stock after selling 64 shares during the quarter. Central Bank & Trust Co.’s holdings in Regeneron Pharmaceuticals were worth $1,086,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of REGN. Marietta Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock worth $6,836,000 after acquiring an additional 2,501 shares in the last quarter. Sepio Capital LP increased its position in shares of Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after acquiring an additional 842 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock worth $517,291,000 after acquiring an additional 814,713 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 3.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after acquiring an additional 955 shares in the last quarter. Finally, KBC Group NV increased its position in shares of Regeneron Pharmaceuticals by 9.4% during the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company’s stock worth $94,779,000 after acquiring an additional 12,793 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on REGN. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price objective for the company. Jefferies Financial Group increased their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. Sanford C. Bernstein raised their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Morgan Stanley reaffirmed an “overweight” rating and issued a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, UBS Group reaffirmed a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $817.67.

Get Our Latest Research Report on REGN

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $572.59 on Tuesday. The firm has a 50-day moving average of $565.30 and a 200-day moving average of $577.02. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,165.85. The company has a market cap of $60.69 billion, a PE ratio of 14.43, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the firm posted $11.56 EPS. The company’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).